ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy CAMBRIDGE, Mass., Sept. 16, 2021 ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

University of North Carolina football team chaplain Mitch Mason has moved into hospice care, he announced on X on Monday. Mason, a former star at Missouri Western State University, continues to battle ...

Beyond sicca symptoms, Sjögren's disease can involve non-glandular manifestations such as dysautonomia and small fiber neuropathy that are often difficult to assess and manage. At this year's American ...

The last time I spoke about Sangamo Therapeutics, Inc. (SGMO) it was regarding a Seeking Alpha article entitled “Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory ...

Sangamo Therapeutics Inc. has received IND clearance from the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy ...

A $3.6 million award from the National Institutes of Health will allow neurosurgical, neurology and neuroscience researchers at The Ohio State University Wexner Medical Center and College of Medicine ...

—This cross-sectional study investigated a possible association between a high GI symptom burden in types 1 and 2 diabetes with the presence of various neuropathies. A high gastrointestinal (GI) ...